Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets EXMKT - Delayed Quote USD

Canntab Therapeutics Limited (CTABF)

Compare
0.0001
0.0000
(0.00%)
As of April 14 at 4:00:00 PM EDT. Market Open.
Loading Chart for CTABF
  • Previous Close 0.0000
  • Open 0.0073
  • Bid --
  • Ask --
  • Day's Range 0.0073 - 0.0073
  • 52 Week Range 0.0001 - 0.0087
  • Volume 2,000
  • Avg. Volume 0
  • Market Cap (intraday) 147,018
  • Beta (5Y Monthly) 1.56
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Mar 8, 2016
  • 1y Target Est --

Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.

canntab.ca

--

Full Time Employees

May 31

Fiscal Year Ends

Recent News: CTABF

View More

Performance Overview: CTABF

Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CTABF
0.00%
S&P 500 (^GSPC)
8.14%

1-Year Return

CTABF
98.63%
S&P 500 (^GSPC)
6.74%

3-Year Return

CTABF
99.97%
S&P 500 (^GSPC)
23.00%

5-Year Return

CTABF
99.97%
S&P 500 (^GSPC)
94.12%

Compare To: CTABF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CTABF

View More

Valuation Measures

Annual
As of 12/5/2024
  • Market Cap

    3.89k

  • Enterprise Value

    1.34M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.07

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    25.65

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -69.60%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    73.48k

  • Net Income Avi to Common (ttm)

    -3.36M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.81k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -612.49k

Research Analysis: CTABF

View More

Company Insights: CTABF

Research Reports: CTABF

View More

People Also Watch